TY - JOUR
T1 - Alteplase in acute ischemic stroke
T2 - Putting the guidelines into practice
AU - Nagaraja, Nandakumar
AU - Adams, Harold P.
N1 - Publisher Copyright:
© 2014 Springer International Publishing Switzerland.
PY - 2014/11
Y1 - 2014/11
N2 - Intravenous recombinant tissue plasminogen activator (rt-PA or alteplase) is the only approved medical intervention for treatment of acute ischemic stroke within the first hours of symptom onset. In this article, we review the preliminary studies of rt-PA in acute ischemic stroke that led to US FDA approval of its use within 3 h of symptom onset. The studies on rt-PA for use beyond 3 h of symptom onset and future reperfusion therapies are discussed. Overviews of the clinical presentation and treatment of acute ischemic stroke and stroke systems of care are described.
AB - Intravenous recombinant tissue plasminogen activator (rt-PA or alteplase) is the only approved medical intervention for treatment of acute ischemic stroke within the first hours of symptom onset. In this article, we review the preliminary studies of rt-PA in acute ischemic stroke that led to US FDA approval of its use within 3 h of symptom onset. The studies on rt-PA for use beyond 3 h of symptom onset and future reperfusion therapies are discussed. Overviews of the clinical presentation and treatment of acute ischemic stroke and stroke systems of care are described.
UR - http://www.scopus.com/inward/record.url?scp=84922003392&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922003392&partnerID=8YFLogxK
U2 - 10.1007/s40263-014-0204-0
DO - 10.1007/s40263-014-0204-0
M3 - Review article
C2 - 25326784
AN - SCOPUS:84922003392
SN - 1172-7047
VL - 28
SP - 1035
EP - 1045
JO - CNS Drugs
JF - CNS Drugs
IS - 11
ER -